Compare APC & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APC | AURA |
|---|---|---|
| Founded | 2025 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 754.9M | 631.6M |
| IPO Year | 2025 | 2021 |
| Metric | APC | AURA |
|---|---|---|
| Price | $14.58 | $7.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $21.25 | $16.60 |
| AVG Volume (30 Days) | 105.2K | ★ 748.9K |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | ★ 13.63% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.94 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.86 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.72 | $4.73 |
| 52 Week High | $21.72 | $9.54 |
| Indicator | APC | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 40.28 | 57.34 |
| Support Level | $14.11 | $6.65 |
| Resistance Level | $19.35 | $7.83 |
| Average True Range (ATR) | 0.80 | 0.41 |
| MACD | 0.06 | 0.11 |
| Stochastic Oscillator | 37.02 | 60.05 |
Arko Petroleum Corp is a fuel distribution company. It operates through three reportable segments: i) Wholesale: Distributes fuel to gas stations, sub-wholesalers, and bulk purchasers, typically under long-term contracts on a cost-plus or consignment basis. ii) Fleet Fueling: Operates proprietary and third-party cardlock locations serving commercial and municipal fleets, and earns commissions from proprietary fuel card sales. iii) GPMP: Supplies fuel to ARKO Retail Sites at cost plus a fixed margin, charges fixed fees to certain sites. The company generates the majority of revenue from the Wholesale segment.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.